Patents Examined by Christine J. Saoud
-
Patent number: 11975045Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.Type: GrantFiled: December 4, 2020Date of Patent: May 7, 2024Assignee: REGENERON PHARMACEUTICALS, INC.Inventor: George Yancopoulos
-
Patent number: 11975080Abstract: This invention provides a DNA comprising any of the following (a) to (c): (a) a DNA comprising any of the base sequences of positions 16 to 831 of SEQ ID NO: 1, positions 16 to 822 of SEQ ID NO: 3, positions 16 to 825 of SEQ ID NO: 5, positions 16 to 819 of SEQ ID NO: 7, positions 16 to 834 of SEQ ID NO: 9, and positions 16 to 828 of SEQ ID NO: 11; (b) a DNA encoding a polypeptide comprising any of the amino acid sequences of positions 1 to 272 of SEQ ID NO: 2, positions 1 to 269 of SEQ ID NO: 4, positions 1 to 270 of SEQ ID NO: 6, positions 1 to 268 of SEQ ID NO: 8, positions 1 to 273 of SEQ ID NO: 10, and positions 1 to 271 of SEQ ID NO: 12; and (c) a complementary strand of the DNA (a) or (b).Type: GrantFiled: March 27, 2018Date of Patent: May 7, 2024Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Eiji Matsuura, Kazuko Kobayashi, Fumiaki Takenaka
-
Patent number: 11976111Abstract: In some aspects, the disclosure relates to activin and/or GDF antagonists and methods of using activin and/or GDF antagonists to treat, prevent, or reduce the progression rate and/or severity of kidney disease, particularly treating, preventing or reducing the progression rate and/or severity of one or more kidney disease-associated complications.Type: GrantFiled: October 4, 2017Date of Patent: May 7, 2024Assignee: Acceleron Pharma Inc.Inventors: Ravindra Kumar, Gang Li
-
Patent number: 11970531Abstract: An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.Type: GrantFiled: September 27, 2022Date of Patent: April 30, 2024Assignee: KYOWA KIRIN CO., LTD.Inventors: Hiroyuki Ariyama, Shinya Ogawa, Tetsuya Kitayama, Takenao Yamada
-
Patent number: 11969458Abstract: The present invention provides a pharmaceutical preparation for treating a cardiovascular disease. Particularly, the present invention provides a formula of a neuregulin pharmaceutical preparation. The formula consist of neuregulin polypeptide, a buffer, a stabilizer, an excipient, a salt, and another component, can ensure the long-term stability of the neuregulin polypeptide, and can be used for treating a heart failure patient or a patient in a risk of the heart failure.Type: GrantFiled: June 5, 2020Date of Patent: April 30, 2024Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.Inventor: Mingdong Zhou
-
Patent number: 11970542Abstract: The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.Type: GrantFiled: November 8, 2018Date of Patent: April 30, 2024Assignees: Fred Hutchinson Cancer Center, Massachusetts Institute of TechnologyInventors: Damian J. Green, Yukang Lin, Oliver W. Press, Alice Tzeng, Karl Dane Wittrup
-
Patent number: 11963999Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.Type: GrantFiled: May 9, 2019Date of Patent: April 23, 2024Assignee: Novartis AGInventors: John Louis Diener, Jiaping Gao, Rick Jerome Schiebinger
-
Patent number: 11958891Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.Type: GrantFiled: January 26, 2018Date of Patent: April 16, 2024Assignee: Surrozen Operating, Inc.Inventors: Zhengjian Zhang, Jennifer Jean Brady, Aaron Ken Sato, Wen-Chen Yeh, Yang Li, Teppei Yamaguchi
-
Patent number: 11952420Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.Type: GrantFiled: September 10, 2021Date of Patent: April 9, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Achal Pashine, Michael L Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
-
Patent number: 11952417Abstract: The present invention is directed towards isolated antibodies that bind to IL12R?1. Specifically, anti-IL12R?1 antibodies, and methods of treatment using the antibodies are disclosed. The antibody is targeted against the beta 1 subunit of the receptors of IL-12 and IL-23 and is capable of blocking signaling by inflammatory cytokines IL-12 and IL-23, which could be useful in treating autoimmune inflammatory diseases, such as inflammatory bowel disease (IBD), RA, and psoriasis.Type: GrantFiled: December 9, 2021Date of Patent: April 9, 2024Assignee: Washington UniversityInventors: Marco Colonna, Cristiane Secca da Silva
-
Patent number: 11944664Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: GrantFiled: August 24, 2021Date of Patent: April 2, 2024Assignee: Novartis AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Patent number: 11919954Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.Type: GrantFiled: September 10, 2021Date of Patent: March 5, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
-
Patent number: 11919968Abstract: The invention provides antibodies that specifically bind to an epitope containing N-acetylglucosamine and specifically bind to an epitope comprising N-acetyl-galactosamine expressed by a cancer cell or an inflammatory cell. Further provided are methods for treating gastrointestinal diseases characterized by inflammatory cells in the intestines or colon in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine and specifically binds to an epitope comprising N-acetyl-galactosamine.Type: GrantFiled: July 13, 2022Date of Patent: March 5, 2024Assignee: B & H Biotechnologies, LLCInventor: Huiru Wang
-
Patent number: 11912784Abstract: Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and/or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate that includes a polymeric moiety that extends the half-life/effectiveness/properties of the antibody when administered to a subject. A method of the present disclosure includes administering one or more doses of an anti-VEGF antibody conjugate to a subject (e.g., human or other mammalian patient) in need of treating an eye disorder, where the anti-VEGF antibody conjugate may be administered less frequently than a standard anti-VEGF therapy to treat the eye disorder.Type: GrantFiled: October 9, 2020Date of Patent: February 27, 2024Assignee: Kodiak Sciences Inc.Inventors: Jason Ehrlich, Pablo Velazquez-Martin, Joel Naor, Daniel Victor Perlroth, Hong Liang
-
Patent number: 11905330Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.Type: GrantFiled: September 26, 2022Date of Patent: February 20, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS CITÉ, SORBONNE UNIVERSITÉInventors: Guido Kroemer, José Manuel Bravo San Pedro
-
Patent number: 11896618Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.Type: GrantFiled: August 13, 2020Date of Patent: February 13, 2024Assignee: Shattuck Labs, Inc.Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
-
Patent number: 11878048Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases.Type: GrantFiled: June 14, 2018Date of Patent: January 23, 2024Assignee: Kymab LimitedInventors: Martina Rauner, Lorenz C. Hofbauer, Uwe Platzbecker, Ulrike Baschant
-
Patent number: 11872271Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.Type: GrantFiled: April 13, 2021Date of Patent: January 16, 2024Assignees: ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.Inventors: Yasufumi Murakami, Shigeki Mukoubata, Hirotada Akiyama, Koji Konomi
-
Patent number: 11866488Abstract: Disclosed herein are compositions including an inhibitor of extracellular human metallothionein (MT) and a pancreatic targeting moiety linked to the inhibitor of extracellular human MT.Type: GrantFiled: January 17, 2019Date of Patent: January 9, 2024Assignees: UNIVERSITY OF CONNECTICUT, JOSLIN DIABETES CENTER, INC.Inventors: Michael A. Lynes, Yu-Hua Tseng, Matthew D. Lynes
-
Patent number: 11858983Abstract: The invention generally relates to anti-sclerostin antibodies having C-terminal modifications, and compositions comprising such antibodies.Type: GrantFiled: September 23, 2022Date of Patent: January 2, 2024Assignee: AMGEN INC.Inventors: Zhe Huang, Jennitte LeAnn Stevens, Greg Flynn, Szilan Fodor, Mark Daris